Negev Labs
Ken Belotsky is an accomplished entrepreneur and business leader with extensive experience in the IT and automotive sectors. Currently serving as the CEO and Co-founder of Negev Labs since January 2024, Ken also holds the position of Partner at Negev Capital since May 2021. Previously, Ken was the Executive Board Director and Executive Chairman at Bright Box from November 2012 to April 2021 and the Chairman of the Supervisory Board at Cloud4Auto Ventures from October 2012 to December 2014. Ken co-founded BrightConsult (Incadea Rus), where, as General Manager and Co-Owner from August 2005 to March 2012, Ken contributed to its growth into a leading developer in the automotive software industry. Ken began the career at Sputnik Labs, advancing from Junior Consultant to COO over four years. Ken's educational background includes studies at Columbia Business School and a degree in Business/Managerial Economics from the Higher School of Economics.
This person is not in any teams
This person is not in any offices
Negev Labs
Negev Labs is a biotech platform company that is focused on the development of neuroplastogens, a novel class of neuroplasticity-promoting compounds that may provide significant clinical benefit in a wide range of indications. Neuroplastogens are new chemical entities that harness the cellular mechanisms of psychedelics but are non-hallucinogenic and bypass the need for in-clinic administration, offering improved therapeutic scalability and patentability. Negev Labs is rapidly advancing with several families of novel neuroplastogens in psychiatric and non-psychiatric diseases, including affective disorders, schizophrenia, neurology, and ophthalmology. The Company’s primary program is expected to commence Phase 1b trials in the third quarter of 2024, with ten additional projects in various stages of pre-clinical development and discovery. Negev Labs was founded by the team behind Negev Capital, a VC with investments in more than 20 psychedelics-focused biotech companies. Utilizing its extensive network, it has built a collaborative community involving over 500 leading researchers in the domain. Negev Labs continuously sources and screens projects from its network, selecting those with the most potential to develop novel therapeutics that can generate real impact for patients. Negev’s methodology includes progressing these compounds through its preclinical platform to achieve Proof of Concept (PoC) in humans. Following successful PoC studies, Negev will either seek to license them to pharmaceutical companies or establish them as standalone companies.